Location & dates EMBL Heidelberg, Germany 5 - 7 Feb 2020 Register Now
Deadlines Registration - 7 Jan 2020 Abstract - 13 Nov 2019

Programme

Got something to say? Tweet it! #EMBLProteome 

or download the poster here.

Day 1 - Wednesday 05 February 2020
TimeSpeaker
11:00-13:00 Registration and Lunch
13:00-13:30 Opening talk
The challenge of expanding the druggable proteome
Adrian Carter, Boehringer Ingelheim, Germany
13:30-15:30

Session 1: Illuminating the challenge and highlighting the opportunity for creating new medicines
Chair: Adrian Carter, Boehringer Ingelheim, Germany

13:30-14:00

Tudor Oprea - University of New Mexico, USA

14:00-14:30

Heiko Runz - Biogen, USA

14:30-15:00

Chemical probes and the chemical biology of cancer
Paul Workman - CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

15:00-15:30

The challenges of creating new medicines: Joining forces to discover novel biological tools and apply new therapeutic modalities
Alleyn Plowright - Sanofi, Germany

15:30-16:00

Coffee break

16:00-18:15

Session 2: Illuminating the most promising proteins by virtue of druggability, human genetics and bioinformatics
Chair: Patrick Aloy, IRB Barcelona, Spain

16:00-16:30

Eytan Ruppin - National Cancer Institute, USA

16:30-16:45

Selected short talk

16:45-17:15

Kristin Brown - GlaxoSmithKline, UK

17:15-17:45

Judith Zaugg - EMBL Heidelberg, Germany

17:45-18:15

Patrick Aloy - IRB Barcelona, Spain

18:15-19:30

Poster Session with beer and snacks
ATC Helices

19:30-21:00

Dinner

21:00-23:00 After Dinner Drinks
ATC Rooftop Lounge
Day 2 - Thursday 06 February 2020
TimeSpeaker
09:00-10:30

Session 3: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 1
Chair: Gerard Drewes, Cellzome, a GlaxoSmithKline company, Germany

09:00-09:30

Giulio Superti-Furga - Center for Molecular Medicine, Austria

09:30-09:45

Selected short talk

09:45-10:00

Selected short talk

10:00-10:30

Stefan Knapp - Goethe University Frankfurt, Germany

10:30-11:00

Coffee break

11:00-11:30

Anne-Claude Gavin - University of Geneva, Switzerland

11:30-11:45

Selected short talk

11:45-12:00 Selected short talk
12:00-12:30

Innate DNA sensing mechanisms in health and disease
Andrea Ablasser - EPFL, Switzerland

12:30-14:00

Meet the speakers and lunch

14:00-16:00

Session 4: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 2
Chair: Anke Müller-Fahrnow, Bayer AG, Germany

14:00-14:30

Kai Johnsson - Max Planck Institute for Medical Research, Germany 

14:30-15:00

Chemical physiology of natural products and antibody conjugates
Gonçalo Bernardes - University of Cambridge, UK and iMM Lisboa, Portugal

15:00-15:30

Training native electrophiles for covalent drug development
Yimon Aye - EPFL, Switzerland

15:30-16:00

Anke Müller-Fahrnow - Bayer AG, Germany

16:00-16:30

Coffee break

16:30-19:00 Session 5: Interrogating the druggable proteome with phenotypic screens
Chair: Herbert Waldmann - Max Planck Institute of Molecular Physiology, Germany
16:30-16:45 Selected short talk
16:45-17:00 Selected short talk
17:00-17:30 Pseudo natural products for chemical biology and drug discovery
Herbert Waldmann - Max Planck Institute of Molecular Physiology, Germany
17:30-18:00

A systems approach to functional precision medicine by deep learning and multi-OMICs
Berend Snijder - ETH Zürich, Switzerland

18:00-18:30 Advancing phenotypic-led drug discovery strategies across diseases of unmet medical need
Neil Carragher - The University of Edinburgh, UK
18:30-19:00 Michael Boutros - German Cancer Research Centre, Germany
19:00-21:00 Dinner
21:00-23:00 After Dinner Drinks, live music
ATC Rooftop Lounge
Day 3 - Friday 07 February 2020
TimeSpeaker
09:00-10:30 Session 6: New engineering approaches for expanding the druggable proteome
Chair: Stefan Knapp, Goethe University Frankfurt, Germany
09:00-09:30 Brenda Andrews - University of Toronto, Canada
09:30-10:00

Maurizio Pellecchia - University of California, Riverside, USA

10:00-10:15

Selected short talk

10:15-10:45

Christine Donahue - GlaxoSmithKline, USA

10:45-11:15

Coffee break

11:15-12:45

Session 7: New engineering approaches for breaking the druggability barrier
Chair: Anne-Claude Gavin, University of Geneva, Switzerland

11:15-11:45

Fragment-based covalent ligand screening to target the ubiquitin system
Katrin Rittinger - The Francis Crick Institute, UK

11:45-12:15

Structure based PROTAC design to expand the druggable Proteome
Alessio Ciulli - University of Dundee, UK

12:15-12:45

Chemical probes in target discovery
Paul Brennan - University of Oxford, UK

12:45-13:15

Identifying gut microbiome contributions to drug metabolism
Michael Zimmermann - EMBL Heidelberg, Germany

13:15-13:30 Closing remarks
13:30-14:00

End of conference
Packed lunch and departure